Sattva Swarup Neelapu

This paper develops a KIR3DL2-directed CAR T-cell therapy for T-cell lymphomas, showing preclinical efficacy and safety in xenograft models.

This study links low stool valerate to CAR T-cell dysfunction in B-cell lymphoma and shows valerate supplementation improves CAR T function.

The paper establishes a PDX repository of large B-cell lymphoma models capturing clinical and molecular diversity, including post-CART19 progression cases.

The paper identifies dysfunctional CD8 CAR T-cells in rrLBCL tumors and shows that pegenzileukin mitigates this dysfunction, improving CAR T-cell responses.

This study finds that clonal hematopoiesis mutations, particularly in DNMT3A, TET2, and ASXL1, are linked to increased toxicity in patients undergoing anti-CD19 CAR T-cell therapy for large B-cell lymphoma.

This study identifies subtype-specific and co-occurring genetic alterations across major B-NHL subtypes using targeted sequencing of 380 genes in 685 tumors.

The paper identifies TCF4 overexpression driven by 18q21.2 gains as a mechanism promoting IgM expression in ABC-like DLBCL and shows BET inhibitors can suppress it.